Search Results

Your search for Christopher Hoimes, MD matches 2 pages

Showing 1 - 2

By Matthew Stenger / August 25, 2023 - Supplement: Genitourinary Oncology Almanac

Enfortumab Vedotin-ejfv Plus Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

In a phase Ib/II study reported in the Journal of Clinical Oncology, Christopher J. Hoimes, MD, and colleagues found that first-line enfortumab vedotin-ejfv plus pembrolizumab produced a high response rate and prolonged response durations in cisplatin-ineligible, previously untreated patients with...

solid tumors

By Christopher Hoimes, MD / July 10, 2021

Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer

The first known clinical trial report of an antibody-drug conjugate was a phase 0/I pharmacodynamic and safety study of a conjugate that targeted carcinoembryonic antigen and delivered a payload of vinca alkaloid in eight patients with ovarian or colorectal cancer.1 This work built on the work of...

May

Today In Oncology

Search Results

Your search for Christopher Hoimes, MD matches 2 pages

Enfortumab Vedotin-ejfv Plus Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer

Glecirasib Shows Efficacy and Safety in KRAS G12C–Mutated NSCLC

Metastatic Castration-Resistant Prostate Cancer Addition of LuPSMA to Enzalutamide

Breast Implant–Related Cancers: Should Our Patients Be Concerned?

Pediatric AML Comparison of Induction Regimens

Older Patients With Newly Diagnosed Hodgkin Lymphoma Preexisting Heart Failure and Survival Outcomes